See more : 7C Solarparken AG (HRPK.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Outlook Therapeutics, Inc. (OTLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Outlook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tokyo Automatic Machinery Works, Ltd. (6360.T) Income Statement Analysis – Financial Results
- Petrotech Oil and Gas, Inc. (PTOG) Income Statement Analysis – Financial Results
- Instituto Hermes Pardini S.A. (PARD3.SA) Income Statement Analysis – Financial Results
- Weihai Guangtai Airport Equipment Co.,Ltd (002111.SZ) Income Statement Analysis – Financial Results
- Iskandar Waterfront City Berhad (1589.KL) Income Statement Analysis – Financial Results
Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.15M | 3.09M | 3.81M | 2.98M | 5.22M | 9.05M |
| Cost of Revenue | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 23.81K | 18.50K | 23.81K | 32.76K | 38.88K | 14.12K |
| Gross Profit | 0.00 | -44.19K | -204.69K | -262.14K | -554.07K | 8.12M | 3.07M | 3.79M | 2.95M | 5.18M | 9.04M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.71% | 99.40% | 99.38% | 98.90% | 99.26% | 99.84% |
| Research & Development | 41,763.05B | 26.45M | 42.33M | 38.96M | 26.34M | 23.81M | 18.50M | 23.81M | 32.76M | 38.88M | 14.12M |
| General & Administrative | 29,940.19B | 26.67M | 20.74M | 12.77M | 9.97M | 9.37M | 14.23M | 15.88M | 21.64M | 12.91M | 7.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 279.68K | -1.90M | -3.85M | -7.25M | -2.69M | -2.47M | 0.00 | 0.00 |
| SG&A | 29,940.19B | 26.67M | 20.74M | 13.05M | 8.08M | 5.52M | 6.97M | 13.19M | 19.17M | 12.91M | 7.32M |
| Other Expenses | 0.00 | 0.00 | -882.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 71,703.24B | 53.13M | 63.07M | 51.73M | 36.31M | 29.33M | 25.48M | 39.69M | 51.93M | 51.78M | 21.44M |
| Cost & Expenses | 0.00 | 53.13M | 63.07M | 51.73M | 36.31M | 32.69M | 28.53M | 39.69M | 54.74M | 51.78M | 21.44M |
| Interest Income | -906.15B | 1.56K | 1.49K | 936.13 | 1.76K | 3.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3,156.96B | 1.56M | 1.49M | 936.00K | 1.76M | 3.47M | 3.89M | 5.63M | 1.47M | 2.30M | 901.05K |
| Depreciation & Amortization | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 3.36M | 3.05M | 2.69M | 2.39M | 1.82M | 878.48K |
| EBITDA | -71,703.24B | -57.38M | -62.87M | -51.46M | -35.76M | -31.11M | -26.79M | -30.03M | -48.95M | -44.74M | -11.51M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -265.98% | -725.17% | -870.73% | -1,656.75% | -857.18% | -127.22% |
| Operating Income | -71,703.24B | -53.13M | -63.07M | -51.73M | -36.84M | -36.30M | -25.44M | -35.88M | -51.76M | -46.56M | -12.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -445.60% | -824.09% | -941.36% | -1,737.10% | -892.13% | -136.92% |
| Total Other Income/Expenses | -3,660.68B | -5.85M | -2.98M | -1.43M | -1.67M | -1.64M | -4.10M | -2.47M | -1.85M | -2.30M | -901.05K |
| Income Before Tax | -75,363.91B | -58.98M | -66.05M | -53.16M | -38.51M | -37.93M | -33.74M | -38.35M | -53.23M | -48.86M | -13.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -465.68% | -1,092.78% | -1,006.10% | -1,786.37% | -936.15% | -146.88% |
| Income Tax Expense | 2.80B | 2.80K | 2.80K | 2.00K | -3.27M | -3.41M | -3.65M | 501.50K | 103.00K | -190.11K | 439.02K |
| Net Income | -75,366.71B | -58.98M | -66.05M | -53.16M | -35.24M | -34.52M | -46.11M | -38.85M | -53.33M | -47.39M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -423.81% | -1,493.57% | -1,019.26% | -1,789.83% | -908.05% | -151.73% |
| EPS | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.54 | -495.71 | -504.47 | -155.35 |
| Weighted Avg Shares Out | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.14K | 107.58K | 93.95K | 88.40K |
| Weighted Avg Shares Out (Dil) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.26K | 107.58K | 93.95K | 88.40K |
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
ISELIN, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the receipt of the...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024
NEW YORK , Nov. 27, 2023 /PRNewswire/ -- Attention Outlook Therapeutics, Inc. ("Outlook") (NASDAQ: OTLK) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between December 29, 2022 and...
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
NEW YORK , Nov. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the "Class...
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Nov. 22, 2023 /PRNewswire/ -- Law Offices of Howard G.
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or "the Company") (NASDAQ:OTLK) for violations of 10(b)...
OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK--(BUSINESS WIRE)---- $OTLK #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook ” or “the Company”) (NASDAQ: OTLK) and certain of its...
Outlook Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Outlook Therapeutics, Inc.
Upcoming Lead Plaintiff Deadline is January 2, 2024 NEW YORK , Nov. 21, 2023 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed against Outlook Therapeutics, Inc. ("Outlook" or...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)
NEW YORK , Nov. 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outlook Therapeutics, Inc.. Shareholders who purchased shares of OTLK during the class period listed are encouraged to contact the firm regarding possible lead...
OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK--(BUSINESS WIRE)---- $OTLK #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outlook Therapeutics, Inc. (“Outlook” or “the Company”) (NASDAQ: OTLK) and certain of its officers....
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024
NEW YORK , Nov. 20, 2023 /PRNewswire/ -- Attention Outlook Therapeutics, Inc. ("Outlook") (NASDAQ: OTLK) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between December 29, 2022...
Source: https://incomestatements.info
Category: Stock Reports